These findings may be of significance to facilitate the development of novel potent and selective p53/MDM2 ligands as putative anti-cancer agents, and more generally to suggest new hypotheses for productively targeting disordered protein regions in structure-based drug design efforts. This evidence concerns the gene TP53 and cancer.